Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...

As Sandoz gears up to launch of one of the most anticipated biosimilars of the year, the company could face near-term ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The WVU Cancer Institute is the first provider in the state to offer a new and promising treatment for extensive-stage small cell lung cancer. Extensive stage means the cancer has spread within the ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Amgen Inc (AMGN) stock saw a decline, ending the day at $275.42 which represents a decrease of $-2.46 or -0.89% from the prior close of $277.88. The stock opened at $276.26 and touched a low of $273.5 ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

The five stocks at the bottom of the barrel, which pulled down the winners, were in fact, losers. Not only were they the tail ...

Rep. Andy Ogles (R-Tenn.) proposed an amendment to the U.S. Constitution that would allow President Trump to serve a third ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...